We investigated the novel recombinant oncolytic adenovirus Ad-delo-sr39TK-RGD, armed with a mutant herpes simplex virus type 1 thymidine kinase (HSV1-sr39TK) as a suicide gene, and explored its antitumor efficacy in combination with HSV1-sr39TK/ ganciclovir (GCV) gene therapy and temozolomide (TMZ). Ad-delo-sr39TK-RGD is an E1-mutated conditionally replicating adenovirus dependent on the human Y-box binding protein 1 (YB-1). Thus, we utilized the YB-1 dependency of the vector to target human glioma cells in vitro, using two-dimensional cell culture and three-dimensional multicellular spheroids, and demonstrated the strong replication competence and oncolytic potential of the virus. The cytotoxicity mediated by HSV1-sr39TK and its prodrug GCV enhanced the oncolytic effect even at o 0.1 μg ml -1 GCV and induced cell killing of 4 95% after adding GCV 0-1 days following infection. An increased bystander effect of viral replication and GCV in co-cultured infected and uninfected cells was observed. Co-administrating Ad-delo-sr39TK-RGD with TMZ and GCV, spheroid growth was reduced drastically. Gamma counting of infected spheroids demonstrated successful accumulation of the radiotracer 18 F-labeled 9-[4-fluoro-3-(hydroxymethyl)butyl] guanine mediated by HSV1-sr39TK. Hence, our results show that the combination of YB-1-dependent virotherapy with suicide genes and TMZ effectively induces glioma cell killing and may allow for in vivo non-invasive imaging within a limited time frame.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common fatal primary brain tumor, characterized by high aggressiveness and recurrence rate. 1, 2 Standard therapy for GBM includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). 2 TMZ is a DNA alkylating agent, which mediates its cytostatic effect through formation of a reactive methyldiazonium cation and DNA methylation of guanine at the O 6 position. 3 Despite recent advances in the therapy of newly diagnosed GBM with concomitant application of radiotherapy and TMZ, the prognosis for GBM patients remains dismal. [4] [5] [6] One of the major challenges for the successful treatment of GBM remains to overcome resistance to standard therapies. Therapeutic resistance often results from the action of the dysfunctional repair mechanisms of the tumor and may be responsible for the refractory character of GBM. 1 The tumor response to therapy can also be highly heterogeneous from one GBM case to the next. 7 Therefore, the development of new targeted therapies for clinical application is crucial. 1 In order to overcome the limitations of standard GBM therapies, alternative treatment strategies are gaining interest. They comprise therapeutic approaches with adenoviral vectors, some of which are already in clinical trials, but with limited success. 8 Among them, oncolytic adenoviruses have a great impact in glioma virotherapy 9 with their ability to replicate within and lyse tumor cells while sparing normal tissue. 10 Conditionally replicating oncolytic adenoviruses can be modified by various genetic manipulations of the adenoviral wild-type genome to replicate selectively in tumor cells. Deletions in the E1A and E1B early viral genes, which are responsible for the initiation of adenoviral replication, limit viral replication to cancer cells with specific dysfunctions. [11] [12] [13] The earliest example of a conditionally replicating adenovirus is the oncolytic adenovirus ONYX-015, although its previously reported ability to replicate selectively within p53-deficient tumor cells 14 was not confirmed. 15 It was demonstrated that nuclear accumulation of the transcription factor Y-box binding protein 1 (YB-1) is responsible for the conditional replication and oncolytic character of an E1A-deleted adenovirus in the presence of YB-1. 16 YB-1 is a multifunctional protein, which is involved in regulation of transcription and translation in multiple signaling pathways, associated with development of cancer malignancy, 17 mRNA splicing, 18 DNA repair,
In oncolytic adenoviruses with a deletion of the E1A splice variant E1A13S, encoding a protein necessary for transactivation of viral gene expression, nuclear YB-1 activates the E2-late promoter and thus adenoviral replication independently of E1A, E1B55K and E4orf6, provided that YB-1 has been already translocated to the nucleus of cancer cells as a result of environmental stress. 16, 24 E1A13S-mutated oncolytic adenoviruses are therefore YB-1 dependent. YB-1 is able to activate the replication of an E1A-deleted oncolytic adenovirus and thus to induce cytopathic effect in various cancer cell lines. 24, 26 Chemotherapeutically induced nuclear accumulation of YB-1 favors an enhanced oncolytic effect of adenovirus dl520 in a novel three-pronged strategy for glioblastoma therapy. 27 Encouraging results in the treatment of malignant glioma in vitro and in vivo were obtained recently by YB-1 virotherapy in combination with TMZ. 28 In order to further improve treatment efficacy and to overcome possible limitations of oncolytic virotherapy, and to monitor the viral fate and biodistribution in the target organs, adenoviruses can be armed with suicide and/or reporter genes. The suicide gene approach is based on the principle that a gene encoding an enzyme capable of converting a nontoxic prodrug into a cellular toxin is transferred into tumor cells. 29 Upon prodrug treatment, the cells expressing the suicide gene are eliminated. The most common applied suicide and reporter gene is Herpes simplex virus type 1 thymidine kinase (HSV1-TK), which converts the prodrug ganciclovir (GCV) into the toxic metabolite GCV-triphosphate that causes cytotoxicity via inhibiting DNA synthesis and inducing apoptosis. [29] [30] [31] To the success of the HSV1-TK/GCV suicide system contributes the so-called bystander effect. It is based on the finding that non-transfected cells acquire sensitivity to GCV when co-cultured with HSV1-TK-transfected cells. 29 The bystander effect is mediated by the transfer of toxic GCV metabolites from HSV1-TK-transfected to neighboring non-transfected cells mostly through gap junctions. 32 Promising antitumor effects were reported for the combination of the HSV1-TK/GCV suicide system with oncolytic adenoviruses in various tumor types. [33] [34] [35] HSV1-TK/GCV can furthermore act synergistically with TMZ in the eradication of malignant glioma. 36 A HSV1-TK mutant, sr39TK, derived by semirandom sequence mutagenesis, displays an increased sensitivity to GCV and is more effective in tumor ablation than wild-type HSV1-TK. 37 HSV1-sr39TK, using the acycloguanosine derivative 18 F-labeled 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine ([ 18 F]-FHBG) as a reporter substrate, is a potent candidate for positron emission tomography imaging with its greater in vivo imaging sensitivity compared with wtHSV1-TK. 38, 39 In this study, we designed an YB-1-dependent oncolytic adenovirus armed with the HSV1-sr39TK gene, based on the previously described oncolytic adenoviral vector Ad-delo3-RGD. 40 The armed adenoviral vector contains a deletion of the transactivation domain CR3 of the E1A13S splice variant, which renders the virus YB-1 dependent and cancer specific, 16, 24 and a deletion of E1B19K, which increases viral spread. 41 An RGD (Arg-Gly-Asp)-motif was additionally inserted into the HI loop of fiber knob to improve tumor infectivity. 42 We characterized the replication competence of the vector, the suicide activity and bystander effect of HSV1-sr39TK/GCV in a glioma cell line. We explored the killing efficacy of the novel armed oncolytic adenovirus based on the combination of oncolysis, HSV1-sr39TK/GCV-mediated cytotoxicity and enhancement of adenoviral replication by TMZ in vitro, including a three-dimensional (3D) spheroid model. In addition to its killing ability, the suitability for non-invasive imaging of the armed oncolytic adenovirus was investigated. Our experimental therapeutic approach shows for the first time a combination of an YB-1-dependent oncolytic adenovirus with a suicide gene and presents encouraging results in the field of combined anti-glioma therapy.
MATERIALS AND METHODS

Cell lines
U87-MG (HTB-14) glioblastoma cells (ATCC, Rockville, MD, USA) were maintained in minimum essential medium with Earle's salts and L-glutamine (GIBCO, Invitrogen, Karlsruhe, Germany) supplemented with 1% non-essential amino acids (GIBCO, Invitrogen). HEK293 cells 43 (Microbix Biosystems, Toronto, Canada) were maintained in Dulbecco's modified Eagle's medium with 1% glutamine (Biochrom, Berlin, Germany). All media were supplemented with 10% fetal calf serum (PAN-Biotech GmbH, Aidenbach, Germany). All cell lines were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .
3D spheroid culture U87-MG derived spheroids were established according to Leske et al. 44 Briefly, 4000 cells were dissociated and seeded on wells of a 96-well plate coated with 1% noble agar (Affymetrix, Cleveland, OH, USA) and maintained in minimum essential medium with Earle's salts and L-glutamine supplemented with 10% fetal calf serum, 1% non-essential amino acids, 1% penicillin/streptomycin (Biochrom), 1% NaHCO 3 , 0.25 μg ml -1 Fungizone (GIBCO, Invitrogen). Cell culture medium was changed 3 times per week. Spheroid diameter was measured with Zeiss Axiovert 135 inverted microscope (Carl Zeiss Microscopy, Jena, Germany) and their volume was calculated using the equation 4/3 × πr 
Adenoviruses
The armed oncolytic adenovirus Ad-delo-sr39TK-RGD is based on the oncolytic vector Ad-delo3-RGD. 40 Key features are: deletion of the CR3 domain of E1A, resulting in lack of the splice variant E1A13S, deletion of E1B19K and in the E3 region, while sparing the adenoviral death protein (ADP) gene in Addelo-sr39TK-RGD. The oncolytic vectors were derived by homologous recombination with the RGD-modified 42 AdEasy backbone (Qbiogene, Carlsbad, CA, USA). The transgene HSV1-sr39TK under the control of a cytomegalovirus promoter and a SV40-poly(A) recognition sequence was cloned upstream of ADP into the E3 region in order to derive Ad-delo-sr39TK-RGD.
Ad-sr39TK is an E1-deleted and partially E3-deleted replication-deficient adenoviral vector, containing CMV-HSV1sr39TK in the E1 region. 38 The Ad-delo-sr39TK-RGD vector was transfected by calcium phosphate precipitation into HEK293 cells after PacI-linearization to derive adenoviral particles. Following expansion on HEK293 cells, all viruses were purified by double CsCl buoyant gradient centrifugations and dialyzed against phosphate-buffered saline (PBS) in a Slide-A-Lyzer Dialysis Cassette (10 K MWCO; Pierce, Rockford, IL, USA). PCR analysis of adenoviral DNA with an E1A-specific primer pair was used as a control to exclude an unintentional contamination with wild-type adenoviruses during the purification process and the genetic modifications of all adenoviral vectors were verified by E1-and E3-specific PCR detection (data not shown). Viral titers (infectious units (i.f.u.) per ml) were determined by Adeno-X Rapid Titer Kit (Clontech Laboratories, Mountain View, CA, USA). Multiplicity of infection (MOI) is defined as i.f.u. per cell in the following, unless otherwise specified.
Infection of two-dimensional (2D) cells and 3D spheroid culture U87-MG cells were infected with adenoviruses using OptiMEM-Glutamax (GIBCO, Invitrogen) for 30 min at 37°C at the indicated MOIs, with subsequent removal of infection medium. For all 3D experiments, U87-MG spheroids were allowed to grow for 3 days after seeding until they reached a volume of 0.1-0.18 mm 3 . Infections were then performed in 50 μl OptiMEM-Glutamax for 30 min at 37°C without removing the spheroids from the coated wells. Subsequently infected spheroids were supplied with fresh medium.
Real-time quantitative PCR (qPCR) analysis of adenoviral DNA replication For quantification of adenoviral and HSV1-sr39TK DNA copy number, U87-MG cells (1 × 10 6 /10 cm-dish) or spheroids were infected at MOI of 10 or 50, respectively, and harvested at different time points after infection by lysis with sodium dodecyl sulfate-Pronase buffer (10 mM Tris/HCl, pH 7.5; 10 mM EDTA, pH 8; 0.5% sodium dodecyl sulfate; 0.5 mg ml -1 Pronase (Roche Applied Sciences, Mannheim, Germany)) overnight at 37°C. Whole-genome DNA was isolated by phenol-chloroform extraction and DNA concentration was determined by spectrometric OD260 nm measurement. For the absolute qPCR replication, analysis of released viral particles DNA was isolated from 100 μl of supernatants of infected (MOI of 10) U87-MG cells 
Real-time mRNA quantification
For the relative real-time quantification (quantitative reverse transcriptase-PCR) of HSV1-sr39TK mRNA, U87-MG cells (1 × 10 6 /10 cm-dish) were infected at MOI of 10 and harvested 6 to 72 h after infection as described above. Total RNA was isolated from the lysates using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and was reverse transcribed into complementary DNA using High capacity cDNA reverse transcription kit (Applied Biosystems). HSV1-sr39TK was amplified and detected by the same primers and probe as used for the absolute quantification of DNA replication. 18S ribosomal RNA was detected as an endogenous control with PreDeveloped TaqMan Assay Reagents Human 18S rRNA 20x (Applied Biosystems). The PCR was performed using qPCR Mastermix Plus (Eurogentec) at standard settings as described above. Experiments were performed in triplicate.
HSV1-sr39TK/GCV-mediated killing assay
In order to verify the oncolytic effect and HSV1-sr39TK/GCV-mediated cytotoxicity, U87-MG cells were infected with varying MOI in 96-well plates (2 × 10 3 cells per well). GCV (Cymeven, Hoffmann-La Roche, GrenzachWyhlen, Germany; 50 mg ml -1 stock dissolved in dH 2 O) was added at different time points after infection and again 72 h after the first addition. Cells were fixed 10 days after infection with 10% trichloroacetic acid (Sigma-Aldrich, St Louis, MO, USA) overnight at 4°C and stained with 0.5% sulforhodamine B (SRB, Sigma-Aldrich; dissolved in 1% acetic acid). To quantify cell survival, dried SRB was dissolved in 10 mM non-buffered Tris and measured photometrically at 590 nm on a Wallac Victor 2 1420 multilabel reader (Perkin Elmer Life and Analytical Sciences, Boston, MA, USA). Cell viability was verified by XTT assay (Cell Proliferation Kit II, Roche Applied Science). All experiments were performed in triplicate.
Bystander effect
The potential bystander effect of GCV in combination with oncolytic potency was evaluated by co-culturing of adenoviral-infected (MOI of 10) and uninfected U87-MG cells at ratios of 100, 50, 30, 17 and 0% infected cells in 24-well plates (5 × 10 4 cells per well) immediately after infection. GCV (10 μg ml -1 ) was added 3 h after co-culturing and repeated after 72 h. The read-out of cell survival was performed 10 days after infection by SRB staining and quantification as described above. The experiment was performed in duplicate.
TMZ-mediated and combined cytotoxicity assay
To analyze the enhancement of oncolysis by cytotoxic drugs, U87-MG cells (2 × 10 3 cells per well in 96-well plates) were pretreated with varying concentrations of TMZ (Sigma-Aldrich; 100 mM stock dissolved in dimethylsulfoxide (Sigma-Aldrich)) for 24 h and infected with MOI of 5-100. Optionally, GCV (0.5 μg ml ) was added 24 h after infection with MOI of 10 in order to assess the effect of combined TMZ and HSV1-sr39TK/GCV treatment. Quantification of cell viability was performed 5-7 days after infection by SRB staining and quantification as described above.
Spheroids were pretreated once with 100 μM TMZ 24 h before and immediately after infection with MOI of 50 and/or treated every 3 days with GCV (0.5 μg ml -1 ) starting 24 h after infection. In order to assess the cytotoxic effects of the adenoviral/TMZ/GCV/TMZ+GCV treatment approaches, spheroid diameter and volume were determined as described above 0, 2, 4, 7 and 10 days after infection.
For the analysis of the TMZ influence on oncolytic adenoviral DNA replication, U87-MG cells (5 × 10 4 cells per well in 24-well plates)/spheroids were infected with MOI of 10 (cells)/50 (spheroids) and treated before and once after infection with 50 μM (cells)/100 μM (spheroids) TMZ. In addition, GCV (0.5 μg ml -1 ) was added 24 h after infection and incubated for additional 48 h (cells) or 24 h (spheroids). DNA extraction and absolute real-time qPCR analyses of adenoviral Fiber DNA copy number were performed as described above.
All experimental settings were performed in triplicate.
Quantification of the infectious titer of viral progeny by end-point dilution assay
U87-MG cells were infected at MOI of 10 as described above and incubated until cytopathic effect was visible. Spheroids were infected with MOI of 50 and/or treated with TMZ and/or GCV as described above. Supernatants containing released viral particles were collected 5 days (monolayer cultures) or 2, 4 and 10 days (spheroids) after infection. Viral titers (plaque forming units (p.f.u.) per ml) were determined by End-Point Dilution Assay on HEK293 cells and repeated twice. Briefly, HEK293 cells were seeded into a 96-well plate and infected with serial dilutions of the supernatants. The infected HEK293 cells were incubated in a humidified atmosphere for 10 days at 37°C. The fraction of cytopathic effect-positive wells for each of the serial dilutions was determined and viral titer was calculated according to the following formula: titer (p.f.u. ml [ 18 F]-FHBG was synthesized at Nuklearmedizinische Klinik und Poliklinik, Technischen Universität München as described previously. 46 
Statistical analyses
All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). The tests used are denoted in the figure legends. P-values o0.05 were considered significant.
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RESULTS
Induction of cytopathic effect, viral replication and expression of HSV1-sr39TK in glioma cells
Cytopathic effect is a hallmark of infection with replicating adenoviruses and is a prerequisite for successful cell killing. The glioma cell line U87-MG was characterized by a high expression level and partial nuclear localization of YB-1, 47 and is therefore suitable for killing by YB-1-dependent adenoviruses. Ad-delosr39TK-RGD was able to induce complete cytopathic effect in U87-MG cells at MOI of 100 48 h after infection, which was as strong as the cytopathic effect mediated by Ad-delo3-RGD (Figure 1a) . Cytopathic effect was microscopically visible at × 10 magnification as plaques of rounded cells detached from the cell monolayer. At MOI of 10, Ad-delo-sr39TK-RGD induced only about 50% cytopathic effect 72 h after infection (data not shown). The cytopathic effect with Ad-delo3-RGD at MOI of 10 was as strong as that with the armed virus (data not shown). Ad-sr39TK did not induce cytopathic effect, which proved its replication-deficient character.
Successful replication of Ad-delo-sr39TK-RGD over time was demonstrated by qPCR analysis, as indicated by the increase in Fiber gene copy number (Figure 1b, left) . The adenoviral DNA accumulated about 180 000-fold from 6 to 72 h after infection, in contrast to the DNA of the replication-deficient adenovirus Ad-sr39TK, which remained constant over time. In comparison with Ad-delo-sr39TK-RGD, Ad-delo3-RGD showed only 8300-fold increase from 6 to 72 h, despite identical E1A genetic backbone. The HSV1-sr39TK copy number (Figure 1b , right) paralleled the increase in Ad-delo-sr39TK-RGD replication, remained constant in the replication-defective Ad-sr39TK and was not detectable in Ad-delo3-RGD.
Five days after infection, 7.9 × 10 6 p.f.u. ml -1 infectious Ad-delosr39TK-RGD particles were released, compared with 3.2 × 10 5 p.f.u. ml -1 of Ad-delo3-RGD (Figure 1c ). The particle release of the oncolytic adenoviruses was in accordance with their DNA replication efficiency and indicated that Ad-delo-sr39TK-RGD could successfully induce glioma cell killing.
As indicated by the quantitative reverse transcriptase-PCR analysis, the mRNA levels of HSV1-sr39TK synthesized by Addelo-sr39TK-RGD increased 50-fold from 6 to 72 h after infection, whereas the transgene mRNA synthesized by Ad-sr39TK remained constant and showed no accumulation over time (Figure 1d ). The increasing transgene expression from Ad-delo-sr39TK-RGD 6 to 72 h after infection was due to the replication competence of the oncolytic virus and thus accumulation of transgene DNA copies, as shown by the replication analysis.
Overlapping time-and dose-dependent HSV1-sr39TK/GCVmediated cytotoxicity and oncolytic effect Initially, we investigated whether the time point of GCV addition and the prodrug dose were crucial for the strength of the HSV1-sr39TK/GCV-mediated cytotoxicity and/or oncolytic effect. The influence of overlapping HSV1-sr39TK/GCV-mediated cell killing and oncolysis was also analyzed.
When GCV was added to cells immediately after infection (0 h), the GCV dose mediating the strongest cytotoxicity was 100 μg ml for Ad-delo-sr39TK-RGD 10 days after infection (Figure 2a ). These data were confirmed by XTT cytotoxicity assay displaying the percentage of metabolically active cells 10 days after infection: after GCV addition directly after infection, cell viability decreased in a dose-dependent way, paralleling SRB quantification (Figure 2b ). Addition of GCV 24, 48 or 72 h after infection revealed effective cell killing at the lowest dose of 0.001 μg ml -1 GCV for oncolytic adenovirus, in contrast to no cytotoxicity of Ad-sr39TK with this GCV dose. Cell killing activity was most effective by applying GCV 48 or 72 h after infection. These results indicate that addition of GCV 48 and 72 h after infection leads to a significant overlap of viral oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity in U87-MG cells regardless of GCV dose, compared with the exclusively prodrug dose-dependent cytotoxicity of the replication-deficient Ad-sr39TK at all time points analyzed (Figure 2a ). Supporting these results of the SRB quantification, when GCV was applied 48 h after infection with Ad-delosr39TK-RGD, no metabolically active cells remained (Figure 2b ). Although cell killing was enhanced by rising GCV doses (Figure 2a ), Ad-sr39TK-infected cells remained metabolically active (Figure 2b) . The IC 50 values of the Ad-sr39TK/GCV-mediated cytotoxicity varied from 9.8 μg ml -1 (72 h) to 0.35 μg ml -1 (24 h) (Figure 2a) .
Although the contribution of suicide system and oncolysis to cell killing could not be clearly dissected, the HSV1-sr39TK/GCVmediated cytotoxicity of the armed oncolytic adenovirus predominated its oncolytic activity from GCV concentrations of 1 to 100 μg ml -1 when applied 0 and 24 h after infection (Figure 2a ). This finding was confirmed by the strong cytotoxic effects of Ad-sr39TK at 1 to 100 μg ml -1 GCV, but less cytotoxicity at lower doses. A peak value of cell survival was observed at 0.1 μg ml -1 GCV after infection with Ad-delo-sr39TK-RGD and GCV addition 0 or 24 h after infection. This gave rise to the assumption that viral replication was prevented by the cytotoxicity of the HSV1-sr39TK/ GCV system, acting on the initial number of infected cells. The inhibition of oncolysis was overcome when GCV was added 48 or 72 h after infection, because the oncolytic effect of the virus had already been initiated before GCV addition and thus predominated over the HSV1-sr39TK/GCV-mediated cytotoxicity.
The cell survival after oncolysis in absence of GCV was between 33 ± 2.98% and 4.2 ± 0.18% 10 days after infection and the cell killing was accordingly 67-96% (data not shown). However, without addition of GCV most of the Ad-delo-sr39TK-RGD-infected cells (89 ± 11.7%) remained metabolically active, despite oncolytic effect (data not shown). In contrast, progressive cell death mediated by Ad-delo-sr39TK-RGD/GCV could be observed microscopically already 3-4 days after infection (data not shown).
These results showed that the oncolytic effect of Ad-delosr39TK-RGD was enhanced by the HSV1-sr39TK/GCV-mediated cytotoxicity in a prodrug dose-dependent way. However, by applying GCV at later time points following infection, the combined action of oncolytic effect and the suicide system induced an equally strong cell killing, so that the oncolytic effect of the virus was not further augmented.
Bystander effect of oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity Subsequently, we analyzed if the bystander effect described for the HSV1-TK/GCV system can be translated to glioma cells infected with oncolytic HSV1-sr39TK-armed adenoviruses. The major challenge is to distinguish between HSV1-sr39TK/GCVmediated bystander effect and bystander effect by replication.
Cell survival decreased dose dependently with increasing ratio of Ad-sr39TK-infected to uninfected glioma cells 10 days after infection (Figure 3 ). Cell survival was 18 ± 0.01% even if only 17% of the whole-cell population was infected with Ad-sr39TK, compared with the same approach without addition of GCV. This indicates the action of a HSV1-sr39TK/GCV-mediated bystander effect. No bystander effect was observed without GCV addition. We demonstrated that the cell survival decreased inversely proportional with increasing ratio of Ad-delo-sr39TK-RGD-infected to uninfected cells 10 days after infection. Cell survival was 45.9 ± 9.7% even when only 17% of the whole-cell population was infected. These data indicate the action of an Ad-delo-sr39TK-RGD-induced, HSV1-sr39TK/GCV-mediated bystander effect. The oncolytic activity of Ad-delo-sr39TK-RGD, shown in the setting without GCV, was directly proportional to the fraction of infected cells. The bystander effect, induced by activated GCV, led to increased cell killing compared with the oncolytic effect alone.
The cooperation of Ad-delo-sr39TK-RGD-mediated oncolysis with the bystander effect, exerted by the HSV1-sr39TK/GCV system, induced efficient cytotoxicity even in cell populations with a low fraction of infected cells.
Enhancement of the oncolytic effect by TMZ and improved cell killing by the combination of oncolysis, TMZ and HSV1-sr39TK/ GCV-mediated cytotoxicity in 2D culture To prove if the oncolytic effect of the adenovirus can be potentiated by treatment with the cytostatic drug TMZ, different experimental approaches were investigated by varying TMZ and viral doses. The IC 50 value of TMZ pretreatment was determined to be over 500 μM in uninfected U87-MG cells. Ad-delo-sr39TK-RGD caused a decrease in cell survival 7 days after infection, even at a MOI of 5 with rising TMZ concentrations (Figure 4a ). Optimal combinations of virus dose and TMZ concentration, which reduced cell survival to o50%, were MOI of 5 or 10 and 25 μM TMZ, and MOI of 20 and 10 μM TMZ.
It was further analyzed if TMZ and GCV can promote enhanced cell killing of infected glioma cells through the combined activity of TMZ-mediated potentiation of oncolysis and HSV1-sr39TK/GCVmediated cytotoxicity (Figure 4b) . A low concentration of GCV (0.5 μg ml -1 ) was chosen in order to be able to detect subtle Bystander effect of oncolysis and HSV1-sr39TK/GCV-mediated cytotoxicity. U87-MG cells were infected at MOI of 10 i.f.u. per cell with HSV1-sr39TK-armed oncolytic and replication-deficient adenoviruses. Infected and uninfected cells were co-cultured at the indicated ratios in the presence of GCV. Cell survival was evaluated by SRB staining and quantified by dye-extraction 10 days after co-culture; n = 2.
Armed YB-1-dependent oncolytic adenovirus Y Kostova et al effects. GCV addition to Ad-delo-sr39TK-RGD-infected TMZuntreated cells and TMZ pretreatment (2.5 μM) of Ad-delosr39TK-RGD-infected GCV-untreated cells both resulted in cell killing of up to 80% (survival 24 ± 10.66% (virus and GCV) and 23 ± 5.34% (virus and TMZ), data not shown). TMZ pretreatment of Ad-delo-sr39TK-RGD-infected cells in combination with GCV led to a potentiated GCV-enhanced cytotoxic effect 5 days after infection, even with only 2.5 μM TMZ. Owing to high efficiency, no further increase in cell killing was observed at higher TMZ doses. The combination of TMZ pretreatment and GCV reduced the cell survival of uninfected and Ad-sr39TK-infected glioma cells, probably due to toxicity of TMZ. These results show efficient TMZ-mediated augmentation of the cell killing activity of Ad-delo-sr39TK-RGD, correlating with viral MOI and cytostatic drug dose. Moreover, a combined effect of oncolytic cell killing, HSV1-sr39TK/GCV-mediated cytotoxicity and TMZ-mediated enhancement of viral oncolysis was demonstrated in 2D glioma culture.
Improved cell killing by combined oncolytic effect, TMZ activity and HSV1-sr39TK/GCV-mediated cell killing in 3D spheroids It was further investigated if the HSV1-sr39TK/GCV-and TMZmediated cytotoxicity in U87-MG monolayer culture can be translated into 3D spheroids of glioma cells. To increase the accessibility of cells in the inner spheroid layers and because of low cell killing at MOI of 10 (data not shown), spheroids were transduced with MOI of 50. As indicated in Figure 5a , a combined application of TMZ (100 μM) and GCV (0.5 μg ml ) induced the strongest reduction of spheroid volume in Ad-delo-sr39TK-RGDinfected spheroids and resulted in growth retardation from day 4 till day 10 after infection, when spheroids were markedly reduced to their initial volume. The TMZ+GCV combination seemed to have a more pronounced effect than TMZ and GCV alone. Seven days after infection, the combined treatment was three times more effective than Ad-delo-sr39TK-RGD alone ('untreated') and two times more effective than Ad-delo-sr39TK-RGD in combination with TMZ. Ad-delo3-RGD-infected spheroids displayed also stronger growth retardation already from day 2 to 4 because of the TMZ treatment, compared with virus alone. Their growth was not further affected by GCV (data not shown). Compared with Ad-delo-sr39TK-RGD, Ad-sr39TK did not induce a pronounced reduction in spheroid volume 10 days after infection, especially in combination with GCV treatment (Figure 5b) . Combination of oncolytic cell killing and HSV1-sr39TK/GCV-mediated cytotoxicity (Ad-delo-sr39TK-RGD+GCV/TMZ+GCV) was superior to HSV1-sr39TK/GCV-mediated cytotoxicity alone (Ad-sr39TK+GCV). Furthermore, detachment of cells from the rim of Ad-delo-sr39TK-RGDand Ad-delo3-RGD-infected and untreated spheroids indicated an enhanced cytopathic effect because of the oncolytic effect 10 days after infection (Figure 5b ). The cytopathic effect in additionally TMZ-or GCV-treated spheroids was not as prominent as the cytopathic effect in untreated spheroids, probably due to the fact that most of the infected cells had been already lysed or their growth was suppressed by the combined treatment. Owing to the induction of cytopathic effect, TMZ addition reduced the growth of Ad-delo-sr39TK-RGD-and Ad-delo3-RGD-infected spheroids We thus demonstrated improved eradication of 3D glioma spheroids by combined action of oncolytic killing, HSV1-sr39TK/ GCV-mediated cytotoxicity and TMZ-mediated enhancement of viral oncolysis.
Enhancement of oncolytic adenoviral replication by TMZ It was investigated if TMZ was able to boost DNA replication of oncolytic adenoviruses in glioma cells as a mechanism of enhanced oncolytic cell killing. In 2D glioma cell culture, continuous TMZ treatment induced an eightfold increase in Ad-delo-sr39TK-RGD DNA copy number, compared with a fivefold replication enhancement of Ad-delo3-RGD, related to infected, untreated samples, 72 h after infection (Figure 6a ). Consistent with its replicationdeficient character, no increase in DNA of Ad-sr39TK was induced by TMZ. Owing to the HSV1-sr39TK/GCV-mediated cytotoxicity and the combined action of TMZ and GCV in mediating cell death shown above, GCV reduced the DNA concentration of Ad-delosr39TK-RGD 3000-fold (without TMZ) and 13 700-fold (with TMZ) 72 h after infection. GCV addition did not alter the replication kinetics of the GCV-insensitive oncolytic adenovirus Ad-delo3-RGD, consequently TMZ and TMZ+GCV led to similar increase in DNA replication. Single or double treatment did not influence the DNA copy number of Ad-sr39TK.
The enhancement of replication of the oncolytic adenoviruses by TMZ was further investigated in infected glioma spheroids 48 h after infection (Figure 6b ). Continuous TMZ application induced a 27-fold replication increase in Ad-delo-sr39TK-RGD DNA, compared with an 11.4-fold increase in Ad-delo3-RGD DNA, related to infected, untreated spheroids. Similar to 2D culture, but to a lesser extent, GCV addition to TMZ-treated or TMZ-untreated spheroids attenuated the replication of Ad-delo-sr39TK-RGD because of the Figure 5 . Improved cell killing by combined oncolytic effect, TMZ activity and HSV1-sr39TK/GCV-mediated cytotoxicity. Spheroids of U87-MG cells were treated with 100 μM TMZ before and once after infection with indicated adenoviruses at MOI of 50 i.f.u. per cell, and/or treated every 3 days with GCV (0.5 μg ml -1 ) starting 24 h after infection. (a) Spheroid growth of Ad-delo-sr39TK-RGD-infected spheroids was monitored on an inverted microscope and volumes were calculated 0, 2, 4, 7 and 10 days after infection (p.i.); n = 3. Ad-delo-sr39TK-RGD, TMZ+GCV vs untreated (infected, but not treated with TMZ or/and GCV): **P = 0.001-0.01 (day 2), ****P o0.0001 (days 4-10), as calculated using two-way analysis of variance (ANOVA) with Tukey's multiple comparison test. (b) Representative images of infected and treated spheroids at day 10 after infection reveal cytopathic effect caused by the oncolytic viruses, especially without treatment (first lane). Significant differences between treatment combinations are marked (squares; Ad-delo-sr39TK-RGD, GCV and TMZ+GCV vs Ad-sr39TK, GCV: ****P o0.0001). Scale bar: 500 μm.
progressive HSV1-sr39TK/GCV-mediated cell death shown in Figure 5 . GCV did not affect Ad-delo3-RGD replication. As expected, TMZ did not induce replication of Ad-sr39TK.
These results show that TMZ caused an efficient augmentation of oncolytic adenoviral replication both in glioma 2D culture and in 3D spheroids. Augmented replication resulted in enhancement of both oncolysis and combined oncolytic and HSV1-sr39TK/GCVmediated cytotoxicity, as shown in Figures 4 and 5 .
Release and infectivity of newly synthesized viral particles from infected 3D glioma spheroids The infectious titer of newly synthesized and released adenoviral particles from infected non-treated spheroids started at 1.42 × 10 6 p.f.u. ml -1 for Ad-delo-sr39TK-RGD 2 days after infection, and was not further enhanced by TMZ treatment (Figure 7 ). GCV and combined TMZ and GCV addition did not result in markedly reduced viral release at these conditions. Four days after infection, viral release increased to 2.94 × 10 11 p.f.u. ml -1 for Ad-delo-sr39TK-RGD. TMZ treatment augmented viral release of Ad-delo-sr39TK-RGD particles 68-fold. The enhancement of viral replication by TMZ ( Figure 6 ) therefore correlated with an increase in the release of new infectious viral particles. Following GCV addition and combined TMZ and GCV treatment, the amount of released Addelo-sr39TK-RGD particles was decreased significantly compared with infected, untreated spheroids. Ten days after infection, TMZ still enhanced viral release of Ad-delo-sr39TK-RGD, although the overall viral titer decreased significantly. According to its replication deficiency, Ad-sr39TK did not show increase in its viral titer over time.
As in 2D culture, Ad-delo-sr39TK-RGD showed successful viral release and re-infectivity of newly synthesized viral particles. Moreover, viral release was enhanced by TMZ as predicted by viral replication.
Adenoviral distribution and HSV1-sr39TK expression in 3D spheroid culture model In order to examine viral dissemination and transgene expression in spheroids transduced with oncolytic adenoviruses, viral hexon Figure 6 . Enhancement of oncolytic adenoviral replication by TMZ. U87-MG monolayer cells (a) and spheroids (b) were treated before and once after infection with indicated adenoviruses with 50 μM (monolayers) and 100 μM TMZ (spheroids). Infections were performed with MOI of 10 and 50 i.f.u. per cell, respectively, for 2D cells and spheroids. GCV (0.5 μg ml ) was added 24 h after infection and incubated for 48 h (monolayers) or 24 h (spheroids). DNA was extracted and subjected to absolute real-time qPCR of Fiber gene for adenoviral replication analysis 72 h (monolayers) or 48 h (spheroids) after infection; n = 3. Asterisks indicate significant differences between treatment approaches. **P = 0.001-0.01, ****P o0.0001, as calculated using one-way analysis of variance (ANOVA) with Tukey's multiple comparison test. ) was added 24 h after infection. The infectivity of newly synthesized and released adenoviral particles (p.f.u. ml -1 ) was analyzed by End-Point Dilution Assay on HEK293 cells 2, 4 and 10 days after infection; n = 2.
Armed YB-1-dependent oncolytic adenovirus Y Kostova et al protein and HSV1-sr39TK expression was analyzed by simultaneous immunodetection (Figure 8 ). Forty-eight hours after infection, the spread of Ad-delo-sr39TK-RGD as well as of Addelo3-RGD was mainly restricted to several outer layers of infected non-drug treated and TMZ-treated spheroids, but progression to the inner layers was also observed. A colocalization of hexon and HSV1-sr39TK expression was observed. Upon GCV and combined TMZ and GCV treatment, adenoviral localization and transgene expression were focused to only few cells of the outer spheroid layer. Regardless of treatment approach, the oncolytic adenoviruses displayed a prominent lateral spread within a single cell layer of some spheroids, rather than a medial spread. This phenomenon was not observed in Ad-sr39TK-infected spheroids, where the overall adenoviral distribution was hampered by the replication-deficient character of the virus. HSV1-sr39TK expression was restricted only to the outer layers of the spheroids, regardless of treatment approach. Considering the replication of oncolytic adenoviruses, an enhanced viral spread was observed both in infected, untreated and TMZ-treated spheroids. On the contrary, GCV or combined TMZ and GCV treatment impaired intercellular viral dissemination, but not viral replication within spheroid cells, as indicated by the strong localized hexon expression, which resulted in decrease of overall particle number. This data were confirmed by the adenoviral DNA replication pattern as described above. Thus, as a prerequisite for cell killing, Ad-delo-sr39TK-RGD displayed successful infectivity and spread within glioma spheroids, as well as HSV1-sr39TK expression.
Uptake of [
18 F]-FHBG by HSV1-sr39TK-expressing glioma cells
To evaluate the potential of the oncolytic adenovirus for noninvasive imaging in combination with HSV1-sr39TK as a reporter gene, in vitro uptake studies with the radiotracer [ 18 F]-FHBG were Figure 8 . Adenoviral distribution and HSV1-sr39TK expression in 3D spheroid culture model. U87-MG spheroids were infected with MOI of 50 i.f.u. per cell of HSV1-sr39TK-armed and non-armed oncolytic and replication-deficient adenoviruses after pre-and posttreatment with 100 μM TMZ and/or GCV (0.5 μg ml -1
) was added once 24 h after infection. Immunodetection of adenoviral Hexon protein and HSV1-sr39TK was performed 48 h after infection. Cell nuclei were visualized using 4´,6´-diamidino-2-phenylindole (DAPI) staining. Representative sections show widest diameter of spheroids. Scale bar: 100 μm.
performed by gamma counting. As a replication-competent adenovirus, Ad-delo-sr39TK-RGD was analyzed for alteration of its transgene activity over time because of the possible influence of viral oncolytic potential on radiotracer accumulation (Figure 9a ). The highest uptake activity was observed 3 days after infection, when HSV1-sr39TK gave rise to a 5.4-fold increase in accumulated radiotracer compared with day 1. GCV addition 24 h before uptake study led to a twofold decrease in radiotracer accumulation, suggesting an attenuated reporter gene activity as a result of the HSV1-sr39TK/GCV-mediated cytotoxicity. Thus, the uptake of radiotracer was positively influenced by the adenoviral replication competence, but was attenuated by HSV1-sr39TK/GCV-mediated cell killing. Under these conditions, cytotoxicity was, however, not as excessive as to abolish radiotracer accumulation completely.
Regarding the uptake activity of HSV1-sr39TK in spheroids, there was a slight decrease in radiotracer accumulation upon TMZ treatment of Ad-delo-sr39TK-RGD-infected spheroids compared with untreated infected spheroids 4 days after infection (Figure 9b ). GCV treatment and combined TMZ and GCV treatment reduced the radiotracer accumulation in Ad-delosr39TK-RGD-infected spheroids compared with untreated infected spheroids, indicating an effect of the HSV1-sr39TK/GCV-mediated cytotoxicity in combination with the oncolytic activity of the virus. The accumulation in untreated Ad-sr39TK-infected spheroids was lower than in untreated Ad-delo-sr39TK-RGD-infected spheroids and was not markedly influenced by treatment with TMZ, GCV or TMZ+GCV.
These data show that the HSV1-sr39TK-expressing oncolytic adenovirus was successful in mediating radiotracer accumulation in both 2D and 3D glioma cell models, also in the context of the HSV1-sr39TK/GCV suicide system. However, the radiotracer uptake rate was not facilitated by enhancement of viral replication through TMZ, presuming that the potentiated oncolytic effect of Ad-delo-sr39TK-RGD by TMZ or the combined effect of TMZ and HSV1-sr39TK/GCV-mediated cytotoxicity resulted in decrease of uptake compared with Ad-sr39TK-infected glioma cells.
DISCUSSION
The objective of this study was to investigate whether the oncolytic effect of replication-competent adenoviruses could be augmented by HSV1-sr39TK/GCV-mediated cytotoxicity and classical TMZ therapy in order to eliminate glioma cells, using the background of YB-1-dependent oncolysis and the finding that YB-1 is upregulated in recurrent glioma. 48 To our knowledge, YB-1-dependent oncolytic adenoviruses have so far not been combined with suicide genes. In addition, the suitability of the HSV1-sr39TK-armed oncolytic adenovirus for non-invasive imaging was explored.
We first demonstrated the strong replication competence and oncolytic potential of Ad-delo-sr39TK-RGD. The improved replication potency of Ad-delo-sr39TK-RGD over the E3-deleted vector Ad-delo3-RGD, despite the identical genetic background of the E1 region, may be caused by the function of the HSV1-sr39TK enzyme. The enzyme is part of the thymidine salvage pathway, catalyzing the transfer of the γ-phosphate from adenosine triphosphate to the 5′-hydroxyl of deoxythymidine to form deoxythymidine-5′-monophosphate. 49 Therefore, it can be hypothesized that the synthesis of adenoviral DNA can be potentiated by increasing the availability of phosphorylated endogenous thymidine by HSV1-sr39TK. The higher release of newly synthesized infectious Ad-delo-sr39TK-RGD viral particles in comparison with Ad-delo3-RGD release may be explained by the expression of the ADP protein from the armed vector. ADP is required for efficient lysis of adenovirus-infected cells and for release of adenoviral progeny. 50 With its strong replication competence, oncolytic potential and successful production of functional progeny, Ad-delo-sr39TK-RGD meets first requirements of successful oncolytic virotherapy. Moreover, the replication of Ad-delosr39TK-RGD was not impaired by the expression of the transgene from the E3 region, which correlated with the replication capacity of the vector. ) addition 24 h before performing the uptake study on day 3; n = 3. (b) Spheroids containing about 1 × 10 5 cells were treated with 100 μM TMZ 24 h before and directly after infection and/or treated with 0.5 μg ml -1 GCV 24 h after infection, and uptake was performed 4 days after infection; n = 3. After labeling of 2D culture and spheroids with 0.1 MBq [
18 F]-FHBG, the accumulated radiotracer because of HSV1-sr39TK activity was released from the cells using 1 M NaOH and measured by gamma counting. Asterisks indicate significant differences between treatment approaches. **P = 0.001-0.01, ***P = 0.0001-0.001, as calculated using one-way analysis of variance (ANOVA) with Tukey's multiple comparison test.
U87-MG glioma cells are susceptible to the suicide gene approach, as indicated by the strong HSV1-sr39TK-/GCV-mediated cytotoxicity in Ad-sr39TK-infected cells. The cell survival upon infection with Ad-delo-sr39TK-RGD was drastically reduced at GCV concentrations of even o0.01 μg ml -1 , indicating that the high sensitivity of HSV1-sr39TK to GCV overlapped with the oncolytic effect of the adenovirus. It was previously reported that HSV1-sr39TK displays a 14-fold decrease in the Michaelis constant (K m ) and an 80-fold higher kinetics with GCV when compared with wild-type TK, which enables the use of GCV at lower, less immunosuppressive doses. 51 The E1A12S protein of Ad-delosr39TK-RGD may also contribute to the HSV1-sr39TK/GCV killing, for it is known that E1A as an S-phase inducer enhances the HSV1-TK/GCV activity. 52 Although the oncolytic effect alone was strong enough to induce cell killing as detected by SRB quantification, the cells were still metabolically active after cytopathic effect, in contrast to infected and concomitantly GCV-treated cells.
In our study, the eradication of tumor cells was more successful when GCV was applied 1 to 3 days after infection than when applied directly after infection, which was consistent with a previous study. 33 The attenuated response of cells infected with replicating adenoviruses to GCV when added immediately after infection could be because of the ability of GCV-triphosphate to inhibit the replication of replication-competent adenoviruses. [53] [54] [55] In our study, the attenuated replication of Ad-delo-sr39TK-RGD by GCV, added immediately after infection, was the most probable explanation for the cell survival at 0.1 μg ml -1 GCV, for this dose was insufficient to induce HSV1-sr39TK/GCV-mediated cytotoxicity. By adding GCV 1 day after infection, the progressive cytotoxicity mediated by HSV1-sr39TK/GCV exerted a deleterious effect on Ad-delo-sr39TK-RGD DNA, as it abolishes the proliferation of virus-infected cells and thus viral replication and spread. When GCV was applied at later time points, the accumulated viral particles were able to overcome the initial inhibitory effect of GCV. Inhibition of adenoviral replication by HSV1-TK/GCV presents an important safety measure and a fail-safe means to control viral dissemination, which may be crucial for in vivo application.
The bystander effect contributed successfully to the HSV1-sr39TK/GCV-mediated cytotoxicity and enabled the eradication of tumor cells containing a small fraction of infected cells. Through its replication competence and the resulting increase in HSV1-sr39TK expression, Ad-delo-sr39TK-RGD enhanced the bystander effect. The transport of toxic metabolites as a bystander mechanism is supported by the expression of gap junctions in GBM cells.
56 U87-MG glioma are susceptible to bystander killing in vitro by GCV-mediated apoptosis induced by metabolic cooperation via gap junctions, but this effect is insufficient in vivo. 57 It was demonstrated that TK from a replication-competent HSV1 was able to enhance connexin 43 subunit (Cx43) expression in a tumor cell line in the presence of GCV. 58 As for oncolytic HSV1, an enhancement of Cx43 expression by the HSV1-TK/GCV suicide system as a bystander mechanism may be also valid in the context of HSV1-TK-armed oncolytic adenoviruses.
Besides 2D cell culture, multicellular 3D spheroids are a feasible model to perform preliminary studies for in vivo effects and to explore adenoviral oncolysis. [59] [60] [61] The oncolytic potency of Addelo-sr39TK-RGD was augmented by TMZ treatment of glioma cells in 2D as well as 3D culture, as shown by the decrease in cell survival and enhancement of viral replication by TMZ. The enhancement of oncolysis is based on the nuclear translocation of the transcription factor YB-1 as a result of TMZ-mediated cytostatic stress and thus stimulation of adenoviral replication, as shown previously for Ad-delo3-RGD. 28 The level of replication enhancement was even stronger in spheroids, indicating that the 3D cell structure facilitated the viral spread. This statement was supported by the finding that Ad-delo-sr39TK-RGD invaded not only the outer layers, but also several inner layers of the spheroids, in contrast to the replication-deficient Ad-sr39TK, as also reported by Grill et al. 61 The restriction of adenoviral replication to the outer replicating layers of spheroids may result from the hypoxic environment of the spheroid core, which can downregulate viral protein expression. 62, 63 Regarding viral dissemination, we show that oncolytic adenoviruses seemed to favor lateral rather than medial spread within spheroids. This could be due to a tight lateral clustering of cells or an uneven distribution of the adenovirusbinding integrins α v β 3 and α v β 5 on the cell surface, as these integrins are known to be overexpressed in the periphery of highgrade gliomas. 64 Although viral spread was impaired by the inhibitory action of GCV upon viral replication, the combined viral and HSV1-sr39TK/ GCV approach in 3D spheroids was more efficient than both oncolytic effect and HSV1-sr39TK/GCV-mediated cytotoxicity alone. The cell killing was therefore rather caused by the bystander effect of GCV than by adenoviral replication alone. However, evidence exist that HSV1-TK-expressing spheroids display lower GCV bystander effect than monolayer culture. 65 Here, this finding was in accordance with the lower Ad-sr39TK-mediated cytotoxicity in spheroids than in 2D culture. The potential bystander effect of GCV in spheroids was, however, enhanced by adenoviral replication at late time points.
There are conflicting data in the literature regarding the efficacy of oncolytic adenoviruses combined with HSV1-TK/GCV suicide therapy. Some studies show that the HSV1-TK/GCV system enhances the oncolytic activity of replication-competent E1B55K-deleted adenoviruses 34, 35 or of replication-competent adenoviruses with deletion of the M r 19.000 glycoprotein (gp19K) coding sequence in the E3 region, 33 whereas other studies demonstrate no further enhancement of E1B-positive oncolytic adenoviruses, especially when the E1B55K protein is functional. [66] [67] [68] [69] In our study, we demonstrate that the E1B55K-expressing HSV1-sr39TK-armed oncolytic adenovirus has a potent antitumor effect by oncolysis alone, especially in 2D glioma culture. In addition, there was an enhancement of the oncolytic effect by combination of oncolytic and HSV1-sr39TK/GCV activity, which was more distinctive in 3D spheroids than in 2D cell culture. We presume that the impaired accessibility of cells within spheroids, leading to a delayed oncolytic effect compared with 2D culture, resembles the in vivo situation more correctly and can be substantially enhanced by the suicide gene system.
We showed that TMZ, by enhancing the oncolytic effect of Addelo-sr39TK-RGD, acted in cooperation with the HSV1-sr39TK-/GCV system both in 2D and 3D. Compared with the sole combination of oncolysis and HSV1-sr39TK-/GCV-mediated cytotoxicity, additional TMZ stimulation induced an earlier onset of cell killing and facilitated the application of less viral load. Considering the inhibition of adenoviral replication by GCV, the therapeutic effect of the triple combination regimen may be increased by applying the prodrug several days after infection, in order to allow viral spread and/or allow for reduced viral and/or drug doses. According to a model of mutual synergism between chemotherapy and YB-1 proposed by Mantwill et al. 25 , chemotherapy leads to increased levels of nuclear YB-1 and consequently enhances adenoviral replication, while viral-mediated nuclear translocation of YB-1 leads to enhanced susceptibility of cells to chemotherapy. Thus, there is strong evidence that the improved killing by the triple combination therapy in our study is based on the mutual synergism between all components. In addition, our results confirm the increased efficiency of YB-1-dependent virotherapy in multimodal over single-mode approaches against GBM in previous studies. 27, 28 The type of cell death in our triple experimental approach and its mode of action have still to be elucidated. TMZ induces apoptosis and senescence in glioblastoma spheroids, 70 but doses up to 100 μM TMZ do not induce strong apoptosis in spheroids. 60 Thus, we conclude that tumor cell eradication in our study resulted from the potentiation of the oncolytic effect by TMZ and the HSV1-sr39TK/GCV-mediated cytotoxicity and not from induction of apoptosis by TMZ.
Multicellular spheroids had been already used as an in vitro model to assess changes in cell viability after treatment with oncolytic adenoviruses by means of a positron emission tomography scan using [ 18 F]-labeled deoxyglucose. 71 To our knowledge, no positron emission tomography imaging of multicellular spheroids using HSV1-sr39TK has been performed by now. Our data demonstrate that Ad-delo-sr39TK-RGD mediated accumulation of radiotracer by enzymatic activity of HSV1-sr39TK in 2D culture and in spheroids. The use of the disseminating oncolytic adenovirus Ad-delo-sr39TK-RGD facilitates nuclear reporter gene delivery and biodistribution and provides first evidence that the therapeutic efficacy of the triple combinatorial approach could be easily monitored in vivo, having in mind that radiotracer uptake rate correlates with cell viability. Nevertheless, the radiotracer application should be well timed in order to achieve an equilibrium between the HSV1-sr39TK/GCV-mediated cytotoxicity, oncolytic killing and tracer accumulation. Regarding the issue of oncolytic toxicity, which could hamper imaging success, the replication-deficient Ad-sr39TK has an advantage over Ad-delosr39TK-RGD for imaging, because of its non-lytic properties.
In summary, arming an YB-1-dependent oncolytic adenovirus with a suicide gene was able to eradicate glioma cells more efficiently than oncolysis alone in an in vitro spheroid model. In 2D culture, however, oncolysis alone was sufficient for tumor cell killing. The potent bystander effect of the suicide gene system allows the application of low viral load and a low GCV dose in order to minimize off-target effects. Enhancement of YB-1-dependent oncolysis by TMZ and combining this approach with HSV1-sr39TK/GCV-mediated cytotoxicity resulted in a potentiation of glioma cell killing. In addition, HSV1-sr39TK-expressing oncolytic adenoviruses allowed for radiotracer accumulation suitable for non-invasive positron emission tomography imaging in cancer therapy. Furthermore, the problem of impaired efficacy of the suicide gene therapy in vivo, caused by a low transduction efficiency, can be circumvented by applying replication-competent oncolytic adenoviruses.
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